PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePRNewsWire • 04/30/24
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness MonthPRNewsWire • 04/29/24
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/08/24
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 03/26/24
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationPRNewsWire • 03/21/24
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpXPRNewsWire • 03/21/24
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 ConferencePRNewsWire • 03/20/24
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024PRNewsWire • 03/12/24
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional TestimonyPRNewsWire • 02/15/24
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility StudiesPRNewsWire • 12/12/23
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock SplitPRNewsWire • 12/04/23
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor DayPRNewsWire • 11/09/23
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023PRNewsWire • 11/01/23
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer DetectionPRNewsWire • 10/31/23